Lindsay Fischer

An implementation of nursing practice changes helped improve the fall rates among patients being treated by the surgical oncology team.

Oncology nurses found that the use of a flexible catheter for subcutaneous immunotherapy is linked with increased safety and satisfaction.

Oncology nurses are in less control of their communication environment compared with other health care providers; however, certain strategies can help them communicate effectively with their patients.

The most important thing that an oncology nurse can do to help a patient navigate their sexual health is repeatedly offer them permission to have conversations surrounding their health.

Belimumab has emerged as a safe and tolerable agent that may be useful for the prophylaxis of chronic graft-vs-host-disease.

Patients who underwent prospective surveillance with bioimpedance spectroscopy were less likely to develop chronic breast cancer–related lymphedema compared with patients who were assessed with tape measure.

Journaling may help patients with sarcoma feel more in control of their symptoms and communicate better with their care team.

A long-term analysis of the phase 3 BILCAP study highlighted modest benefit for patients with resected biliary tract cancer who received capecitabine following surgery.

New research suggests that olaparib treatment interruption or dosage reduction is not linked with inferior survival outcomes in patients with BRCA1/2–mutated, platinum-sensitive, recurrent ovarian cancer.

In this episode of “The Vitals,” Heidi Donovan, PhD, RN, discusses novel symptom management intervention for women with recurrent ovarian cancer.

TTX-030 is the first fully human IgG4 antibody designed to target CD39, as well as the first CD39 inhibitor to undergo a phase 1 clinical trial.

Patients with YAP1 and inflamed T-cell expressing extensive-stage small cell lung cancer experienced superior overall survival following treatment with durvalumab and etoposide.

The PARP inhibitor rucaparib significantly prolonged progression-free survival compared with placebo as a first-line maintenance treatment in previously treated patients with ovarian cancer.

Courtney Arn, APRN-CNP, a nurse practitioner who supported cohorts D and K of the KEYNOTE-158 study, discusses the recent approval of pembrolizumab for patients with MSI-H/dMMR advanced endometrial carcinoma.

A new method of developing CAR T-cell products produced infusion-ready cells in under 24 hours.

New data demonstrate that regular exercise can help patients with breast cancer mitigate the physical and mental treatment–related side effects that might impact their quality of life.

A post-hoc efficacy analysis of KEYNOTE-048 found that CPS scores were linked to immunotherapy efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

In this episode of “The Vitals,” Hamid Emamekhoo, MD, discusses the evolving treatment landscape of kidney cancer.

Childhood cancer survivors may benefit from high-risk obstetric care despite being able to conceive and give birth safely.

Together, the associations stated that, like many other nurses following this case, they were hoping for a different outcome.

Two healthcare professionals with Cancer Treatment Centers of America® (CTCA) Phoenix, a comprehensive care and research center recently recognized with Magnet® distinction, discuss the importance of transparency in nursing satisfaction and engagement.

Oncology Nursing News® speaks with Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, about the significance of the relatlimab/nivolumab approval for patients with unresectable or metastatic melanoma.

Findings from the KEYNOTE-091 trial showed that patients with non–small cell lung cancer who were treated with pembrolizumab following complete resection and chemotherapy had a 24% decreased risk of recurrence compared with a control arm.

Oncology Nursing News® speaks with the Charles E. Geyer, MD, FACP, an investigator with the phase 3 OlympiA trial to better understand the significance of olaparib’s approval and to determine what oncology nurses need to know about the new agent.

Lutetium-177-PSMA-617 is now FDA-approved for the treatment of patients with metastatic castration-resistant prostate cancer who have already received androgen receptor pathway inhibition and taxane-based chemotherapy.

The PARP inhibitor demonstrated impressive overall survival benefit in patients with BRCA-mutated, HER2-negative, high-risk early breast cancer.

New research shows that women are at an increased risk of developing an adverse event following cancer therapy compared with their male counterparts. This risk is particularly elevated among patients receiving immunotherapy.

The FDA has approved pembrolizumab to treat patients with endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, as determined by an FDA-approved test.

The ongoing FLORA-5 trial will assess whether the addition of oregovomab to a standard chemotherapy regimen will improve progression-free and overall survival in patients with advanced epithelial ovarian cancer.

The doublet regimen of relatlimab/nivolumab has been approved for adults with unresectable or metastatic melanoma.